29
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Submit your digital health research with an established publisher
      - celebrating 25 years of open access

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hospital Epidemics Tracker (HEpiTracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers

      research-article
      , MD 1 , 2 , , , MD 2 , 3 , 4 , 5 , , MD 6 , , MD 7 , , MD 8 , , MD 2 , 3 , 4 , 5 , , MD 2 , 9 , , BSc 10 , , BSc 10 , , BSc 10 , , BSc 10 , , BSc 10 , , PhD 11 , , PhD 12 , , BSc 13 , , PhD 14 , , BSc 15 , , MD 2 , 15 , 16 , , PhD 17 , , BSc 18 , , BSc 18 , , BSc 18 , , BSc 18 , , BSc 18 , , MD 1 , 2
      (Reviewer), (Reviewer), (Reviewer)
      JMIR Public Health and Surveillance
      JMIR Publications
      app, COVID-19, coronavirus, e-medicine, monitoring, symptoms, surveillance

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Hospital workers have been the most frequently and severely affected professional group during the COVID-19 pandemic, and have a big impact on transmission. In this context, innovative tools are required to measure the symptoms compatible with COVID-19, the spread of infection, and testing capabilities within hospitals in real time.

          Objective

          We aimed to develop and test an effective and user-friendly tool to identify and track symptoms compatible with COVID-19 in hospital workers.

          Methods

          We developed and pilot tested Hospital Epidemics Tracker (HEpiTracker), a newly designed app to track the spread of COVID-19 among hospital workers. Hospital staff in 9 hospital centers across 5 Spanish regions (Andalusia, Balearics, Catalonia, Galicia, and Madrid) were invited to download the app on their phones and to register their daily body temperature, COVID-19–compatible symptoms, and general health score, as well as any polymerase chain reaction and serological test results.

          Results

          A total of 477 hospital staff participated in the study between April 8 and June 2, 2020. Of note, both health-related (n=329) and non–health-related (n=148) professionals participated in the study; over two-thirds of participants (68.8%) were health workers (43.4% physicians and 25.4% nurses), while the proportion of non–health-related workers by center ranged from 40% to 85%. Most participants were female (n=323, 67.5%), with a mean age of 45.4 years (SD 10.6). Regarding smoking habits, 13.0% and 34.2% of participants were current or former smokers, respectively. The daily reporting of symptoms was highly variable across participating hospitals; although we observed a decline in adherence after an initial participation peak in some hospitals, other sites were characterized by low participation rates throughout the study period.

          Conclusions

          HEpiTracker is an already available tool to monitor COVID-19 and other infectious diseases in hospital workers. This tool has already been tested in real conditions. HEpiTracker is available in Spanish, Portuguese, and English. It has the potential to become a customized asset to be used in future COVID-19 pandemic waves and other environments.

          Trial Registration

          ClinicalTrials.gov NCT04326400; https://clinicaltrials.gov/ct2/show/NCT04326400

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

          The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              COVID-19: the case for health-care worker screening to prevent hospital transmission

              The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed unprecedented strain on health-care services worldwide, leading to more than 100 000 deaths worldwide, as of April 15, 2020. 1 Most testing for SARS-CoV-2 aims to identify current infection by molecular detection of the SARS-CoV-2 antigen; this involves a RT-PCR of viral RNA in fluid, typically obtained from the nasopharynx or oropharynx. 2 The global approach to SARS-CoV-2 testing has been non-uniform. In South Korea, testing has been extensive, with emphasis on identifying individuals with respiratory illness, and tracing and testing any contacts. Other countries (eg, Spain) initially limited testing to individuals with severe symptoms or those at high risk of developing them. Here we outline the case for mass testing of both symptomatic and asymptomatic health-care workers (HCWs) to: (1) mitigate workforce depletion by unnecessary quarantine; (2) reduce spread in atypical, mild, or asymptomatic cases; and (3) protect the health-care workforce. Staff shortages in health care are significant amidst the global effort against coronavirus disease 2019 (COVID-19). In the UK, guidance for staffing of intensive care units has changed drastically, permitting specialist critical care nurse-to-patient ratios of 1:6 when supported by non-specialists (normally 1:1) and one critical care consultant per 30 patients (formerly 1:8–1:15). 3 Fears of the impact of this shortage have led to other measures that would, in normal circumstances, be considered extreme: junior doctors’ rotations have been temporarily halted during the outbreak; annual leave for staff has been delayed; and doctors undertaking research activities have been redeployed. Workforce depletion will not only affect health care; the Independent Care Group, representing care homes in the UK, has suggested that social care is already “at full stretch”, 4 with providers calling for compulsory testing of social and health workers to maintain staffing. In spite of this, a lack of effective testing has meant that a large number of HCWs are self-isolating (125 000 HCWs, according to one report 5 ). In one small sample, only one in seven self-isolating HCWs were found to have the virus. 6 A letter to National Health Service (NHS) Trust executives on April 12, 2020, outlined that priority is being given to staff in critical care, emergency departments, and ambulance services to prevent the impact of absenteeism in those areas. 7 Increased testing capacity will enable all staff who are self-isolating unnecessarily to bolster a depleted workforce. Asymptomatic HCWs are an underappreciated potential source of infection and worthy of testing. The number of asymptomatic cases of COVID-19 is significant. In a study of COVID-19 symptomatic and asymptomatic infection on the Diamond Princess cruise ship, 328 of the 634 positive cases (51·7%) were asymptomatic at the time of testing. 8 Estimated asymptomatic carriage was 17·9%. 8 Among 215 obstetric cases in New York City, 29 (87·9%) of 33 positive cases were asymptomatic, 9 whereas China's National Health Commission 10 recorded on April 1, 2020, that 130 (78%) of 166 positive cases were asymptomatic. Moreover, transmission before the onset of symptoms has been reported11, 12, 13, 14 and might have contributed to spread among residents of a nursing facility in Washington, USA. 15 Furthermore, evidence from modelled COVID-19 infectiousness profiles suggests that 44% of secondary cases were infected during the presymptomatic phase of illnesses from index cases, 16 whereas a study of COVID-19 cases in a homeless shelter in Boston, MA, USA, implies that individual COVID-19 symptoms might be uncommon and proposed universal testing irrespective of symptomatic burden. 17 Substantial asymptomatic transmission might also mean that current estimates of the basic reproduction number, R0, for COVID-19 are inaccurate. 18 HCW testing could reduce in-hospital transmission. In a retrospective, single-centre study in Wuhan, 41% of 138 patients were thought to have acquired infection in hospital. 19 At the Royal Gwent Hospital in Newport, Wales, approximately half of the emergency room workforce have tested positive. 20 Blanket testing near Venice, Italy, helped to identify asymptomatic cases and might have helped eliminate SARS-CoV-2 in a village. 21 Moreover, asymptomatic and presymptomatic HCWs continue to commute to places of work where personal protective equipment (PPE) might be suboptimal. This disease spread could, in turn, propagate out of hospitals: during a period of lockdown asymptomatic COVID-19 carriage among hospital staff could conceivably act as a potent source of ongoing transmission. Protecting the health of HCWs is paramount when staffing is limited. As well as by the provision of adequate PPE, the wellbeing of HCWs can be promoted by ensuring that infected colleagues are promptly tested and isolated. The scale of this problem is not yet fully understood, nor is the full potential for asymptomatic and presymptomatic HCWs to transmit infection to patients who do not have COVID-19, other HCWs, or the public. However, given that asymptomatic transmission has been documented, utmost caution is urged.11, 12, 13, 14 Our own NHS Trust at University College London Hospitals, London, UK, will soon be testing asymptomatic HCWs. In partnership with the Francis Crick Institute in London, UK, where COVID-19 testing will be performed, this initiative is an attempt to further limit nosocomial transmission. It could also alleviate a critical source of anxiety for HCWs. 22 A healthy, COVID-19-free workforce that is not burned out will be an asset to the prolonged response to the COVID-19 crisis. As testing facilities increase in number and throughput in the coming weeks, testing should aim to accommodate weekly or fortnightly screening of HCWs working in high-risk areas. There is a powerful case in support of mass testing of both symptomatic and asymptomatic HCWs to reduce the risk of nosocomial transmission. At the time of writing, the UK is capable of performing 18 000 tests per day, 23 with the Health Secretary targeting a capacity of 100 000 tests per day by the end of April, 2020. Initially, the focus of testing was patients, with NHS England stating only 15% of available testing would be used to test NHS staff. 24 Although this cap has been lifted, symptomatic HCWs, rather than asymptomatic HCWs, are currently prioritised in testing. This approach could mean that presymptomatic HCWs who are capable of transmitting the virus are not being tested; if they were tested and found to be COVID-19 positive, they could be advised to isolate and await the onset of symptoms or, if no symptoms develop, undergo repeat testing. As countries seek to flatten the growth phase of COVID-19, we see a significant opportunity in expanding testing among HCWs; this will be critical when pursuing an exit strategy from strict lockdown measures that curb spread of the virus.
                Bookmark

                Author and article information

                Contributors
                Journal
                JMIR Public Health Surveill
                JMIR Public Health Surveill
                JPH
                JMIR Public Health and Surveillance
                JMIR Publications (Toronto, Canada )
                2369-2960
                Jul-Sep 2020
                21 September 2020
                21 September 2020
                : 6
                : 3
                : e21653
                Affiliations
                [1 ] Hospital Universitario La Princesa Universidad Autónoma de Madrid Madrid Spain
                [2 ] Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES) Instituto de Salud Carlos III (ISCIII) Madrid Spain
                [3 ] Unidad de Control del Tabaco Centro Colaborador de la OMS para el Control del Tabaco, Institut Català d'Oncologia-ICO Hospitalet de Llobregat Barcelona Spain
                [4 ] Grupo de Control y Prevención del Cáncer Institut d'Investigació Biomèdica de Bellvitge-IDIBELL Hospitalet de Llobregat Barcelona Spain
                [5 ] Departamento de Ciencias Clínicas Facultad de Medicina, Universitat de Barcelona Hospitalet de Llobregat Barcelona Spain
                [6 ] Servicio de Neumología Hospital de Can Misses Ibiza Spain
                [7 ] Servicio de Neumología Hospital Lucus Augusti Lugo Spain
                [8 ] Servicio de Neumología Hospital Álvaro Cunqueiro Vigo Spain
                [9 ] Servicio de Neumología Hospital de Alta Resolución de Loja Loja Spain
                [10 ] Fundación Teófilo Hernando Madrid Spain
                [11 ] CIMNE - International Center for Numerical Methods in Engineering Barcelona Spain
                [12 ] SAVANA Med Madrid Spain
                [13 ] Unidad de Metodología IIS del Hospital Universitario La Princesa Madrid Spain
                [14 ] ISGlobal Universitat Pompeu Fabra Barcelona Spain
                [15 ] IdISBa Palma Spain
                [16 ] Servicio de Neumología Hospital Universitari Son Espases Palma Spain
                [17 ] Institute for Research in Technology Universidad Pontificia Comillas Madrid Spain
                [18 ] ASELCIS Consulting Madrid Spain
                Author notes
                Corresponding Author: Joan B Soriano jbsoriano2@ 123456gmail.com
                Author information
                https://orcid.org/0000-0001-9740-2994
                https://orcid.org/0000-0003-4239-723X
                https://orcid.org/0000-0002-5223-4234
                https://orcid.org/0000-0003-2652-6847
                https://orcid.org/0000-0001-7407-5249
                https://orcid.org/0000-0002-3475-8704
                https://orcid.org/0000-0003-2356-9366
                https://orcid.org/0000-0001-5284-8984
                https://orcid.org/0000-0001-7447-0003
                https://orcid.org/0000-0001-9726-5969
                https://orcid.org/0000-0003-4020-9688
                https://orcid.org/0000-0001-7098-3477
                https://orcid.org/0000-0002-2445-5398
                https://orcid.org/0000-0002-1036-1673
                https://orcid.org/0000-0001-9781-9626
                https://orcid.org/0000-0002-8457-1489
                https://orcid.org/0000-0002-7678-0205
                https://orcid.org/0000-0002-6388-8209
                https://orcid.org/0000-0002-5506-9027
                https://orcid.org/0000-0003-2891-7331
                https://orcid.org/0000-0003-4944-6794
                https://orcid.org/0000-0002-0522-2249
                https://orcid.org/0000-0002-3658-172X
                https://orcid.org/0000-0001-8841-1469
                https://orcid.org/0000-0001-7451-4133
                Article
                v6i3e21653
                10.2196/21653
                7511223
                32845852
                7b6985e8-a692-4d22-a519-49563c1ee5de
                ©Joan B Soriano, Esteve Fernández, Álvaro de Astorza, Luis A Pérez de Llano, Alberto Fernández-Villar, Dolors Carnicer-Pont, Bernardino Alcázar-Navarrete, Arturo García, Aurelio Morales, María Lobo, Marcos Maroto, Eloy Ferreras, Cecilia Soriano, Carlos Del Rio-Bermudez, Lorena Vega-Piris, Xavier Basagaña, Josep Muncunill, Borja G Cosio, Sara Lumbreras, Carlos Catalina, José María Alzaga, David Gómez Quilón, Carlos Alberto Valdivia, Celia de Lara, Julio Ancochea. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 21.09.2020.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on http://publichealth.jmir.org, as well as this copyright and license information must be included.

                History
                : 21 June 2020
                : 23 July 2020
                : 29 July 2020
                : 21 August 2020
                Categories
                Original Paper
                Original Paper

                app,covid-19,coronavirus,e-medicine,monitoring,symptoms,surveillance

                Comments

                Comment on this article